Get started
MEDTRONIC PLC DL-,0001MM

MEDTRONIC PLC DL-,0001

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

2M6 trade ideas

MedTronic - What is your Opinion? Shall we discuss it?This time as an experiment, why don't we discuss the prospects before taking action- HERE IS MY CONTRIBUTION - can we all collaborate ? What Medtronic is doing right: It looks like these guys make transplant patients nervouse, nervous to have their pace makers hacked. That has t increase liability does it not? Proactive identification: Medtronic identified the cybersecurity vulnerability in their Paceart Optima system during routine monitoring. Prompt reporting: The company reported the issue to the U.S. Cybersecurity & Infrastructure Security Agency (CISA). Transparency: Medtronic issued a security bulletin and provided information about the vulnerability. Rapid response: The company developed and released an update (v1.12) to address the vulnerability. Customer communication: Medtronic notified healthcare organizations about the issue and provided instructions to eliminate the vulnerability. Commitment to security: The company stated they take potential cybersecurity vulnerabilities very seriously. Vulnerabilities: Critical flaw in Paceart Optima system: The vulnerability (CVE-2023-31222) has a critical CVSS score of 9.8 out of 1035. Remote code execution risk: If exploited, the vulnerability could allow unauthorized users to perform remote code execution or launch denial-of-service attacks. Data compromise: Hackers could potentially delete, steal, or modify cardiac device data. Network penetration: The vulnerability could be used as a gateway for further network penetration in healthcare organizations. Legacy devices: The issue affects older versions of the software (v1.11 and earlier), highlighting the need for regular updates. Optional feature risk: The vulnerability exists in an optional messaging feature, which if enabled, exposes the system to potential attacks. Historical vulnerabilities: Medtronic has faced previous scrutiny for security issues in other devices, such as insulin pumps and defibrillators.
N
by imcnf5c4ff
Medtronic plc. The price is currently hovering near the upper band, which suggests the stock may be experiencing some upward momentum. Support: Around $87, where the price found buyers recently after a pullback. Resistance: Immediate resistance is near $91.50, which is the high from a recent candle. The middle line of the Bollinger Bands appears to be a 20-period simple moving average (SMA). The price is above this line, suggesting a short-term uptrend is intact. The stock has rebounded from the lower band earlier in September and has been on a gradual rise, indicating buyers stepping in after the dip. Over the past month, MDT has shown bullish momentum, but the recent pause near the upper Bollinger Band indicates that the stock could face resistance at this level. The stock is currently in an uptrend, but the possibility of a short-term pullback exists if the price cannot break above the current resistance zone. MDT is in a short-term uptrend, as indicated by the price trading above the middle Bollinger Band and the recent rally. The next critical level to watch is the resistance around $91.50. A breakout above this could see the stock moving higher, while a failure could lead to a pullback towards the $87 support level. Monitoring the Bollinger Band for any squeeze or expansion can provide clues on future volatility.
NLong
by Sahrin
Medtronic leverages AI to enhance medical device developmentMedtronic Plc, a leading global medical device manufacturer, increasingly integrates artificial intelligence (AI) into its operations to enhance business efficiency and spearhead new developments. The company has positioned AI as a central element of its research and development strategy, employing machine learning algorithms to expedite the design and testing phases of new medical devices. The application of such AI solutions spans various functions, from optimising materials and device geometry to validating product performance via virtual simulations. Although Medtronic projects single-digit revenue growth for 2025, the escalating global demand for healthcare products may lead to more substantial growth. Exploring potential trading opportunities, let's analyse the stock chart of Medtronic Plc (NYSE: MDT) from a technical analysis perspective: On the Daily (D1) timeframe, Medtronic's stock has established a resistance level at 84.20 USD and support at 81.75 USD. An initial uptrend is evident, indicating the potential for further increases. However, if a downtrend starts, the downside target could be set at 70.10 USD. If the current uptrend continues and the stock price breaks through the resistance at 84.20 USD, there could be a buying opportunity with a short-term target of 89.30 USD. For those considering a medium-term investment strategy, the stock price might rise to 95.50 USD if the positive momentum persists. __ Ideas and other content presented on this page should not be considered as guidance for trading or an investment advice. RoboMarkets bears no responsibility for trading results based on trading opinions described in these analytical reviews. The material presented and the information contained herein is for information purposes only and in no way should be considered as the provision of investment advice for the purposes of Investment Firms Law L. 87(I)/2017 of the Republic of Cyprus or any other form of personal advice or recommendation, which relates to certain types of transactions with certain types of financial instruments. Risk Warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69.88% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
N
by RoboMarkets
Medtronic Beats Fourth-Quarter Estimates But Shares Down 2.44%Medtronic ( NYSE:MDT ), a health tech firm, has beat Wall Street estimates for quarterly profit and revenue in Q4 due to a pickup in surgical volumes at hospitals. The company's financial performance has grown due to a resurgence in demand as people, especially older adults, opted for medical procedures deferred during the COVID-19 pandemic. Medtronic forecasts fiscal 2025 adjusted per-share profit in the range of $5.40 to $5.50, with its midpoint in line with analysts' average estimate of $5.45. Medtronic ( NYSE:MDT ) joins medical device makers such as Abbott Laboratories and Boston Scientific that have also benefited from soaring demand for non-urgent surgeries. The company took an adjusted charge of $439 million in the fourth quarter, higher than its previously disclosed estimate of between $350 million and $425 million, related to its decision to exit its unprofitable ventilator product line and reorganize the respiratory and patient monitoring businesses. Sales at the company's diabetes unit, which returned to growth in the U.S. last quarter, rose 10.9% in the quarter ended April 26. However, sales at Medtronic's heart devices unit, its biggest revenue driver, fell 5.2% to $3.13 billion, missing analysts' estimate of $3.14 billion. The second-biggest unit by revenue, neuroscience, which makes medical devices and implants used in the treatment of the spine and musculoskeletal system, posted a 5.6% rise in sales, topping analysts' expectations. Medtronic ( NYSE:MDT ) reported Q4 worldwide revenue of $8.589 billion, an increase of 0.5% as reported and 5.4% on an organic basis. The organic revenue results reflect broad-based growth across the company, with mid-single digit or higher organic revenue growth in all four segments. FY24 worldwide revenue of $32.364 billion, an increase of 3.6% as reported and 5.2% on an organic basis, was reported. The company's momentum is building into the new fiscal year, with new product cycles in some of MedTech's most attractive markets and enhanced as AI is applied across the portfolio. Technical Outlook Despite profit beat, Medtronic ( NYSE:MDT ) stock is down 2.44% as of the time of writing trading with a Relative Strength Index (RSI) of 52.24 which is poised for a trend reversal in the near to long term. The daily price charts depicts a long wick Doji which means indecision among buyers and sellers.
N
by DEXWireNews
5/22/24 - $mdt - uninteresting, need a heavy discount to care :/5/22/24 - vrockstar - NYSE:MDT - valuation interesting at 17x PE for what looks like a nice cash generator (6% fcf yield minimally). the issue is really growth which is either flat at best this yr or probably -ve. these unfortunatley are simply un-ownable companies in this tape which is prioritizing growth-ONLY. so while i'd be interested lower and am setting a flag (good mgn, good cash gen), it's probably not something i'd want to swing long on into the print b/c it's something that (second order thinking) i'd not be willing to size up on a miss, and also probably we won't get a catalyst enough to size up into a beat either. i'd stay on the sideline and get greedy if this one's on your radar. setting my tgt closer to $70, which while I don't believe will go there this print, is the only px i'd be willing to engage.
N
by VROCKSTAR
Stocks pairs trading: BMY vs MDTIn the medical device and pharmaceutical sectors, contrasting financial metrics and market dynamics between Medtronic plc (MDT) and Bristol-Myers Squibb Company (BMY) present a compelling scenario for investors. Based on their respective financial performances and market positions, it could be strategic to consider buying BMY while contemplating selling MDT. Reasons to Prefer BMY Over MDT: Earnings Per Share (EPS): BMY's EPS of $3.94 is higher than MDT's $3.08. This suggests that BMY is currently more profitable and efficient in its operations compared to MDT. Forward Price-to-Earnings (P/E) Ratio: BMY's forward P/E is significantly lower at 6.67 compared to MDT's 14.49. A lower P/E ratio often indicates that the stock is undervalued relative to its earnings potential. Dividend Yield: BMY offers a higher dividend yield of 4.58% compared to MDT's 3.35%. This makes BMY a more attractive choice for income-focused investors. Profit Margin: BMY has a higher profit margin of 18.44%, compared to MDT’s 12.83%. A higher profit margin typically indicates better control over costs and more efficiency in operations. Year-to-Date Performance: Although both stocks have experienced declines, MDT's performance (-1.65% YTD) has been relatively better than BMY's significant drop (-31.87% YTD). However, BMY's lower valuation and higher dividend yield might offer a more compelling buy opportunity in anticipation of a potential rebound. Decision: Buy 2 BMY: Given its higher profitability, attractive dividend yield, lower valuation, and potential for rebound, BMY presents a promising investment for both value and income-seeking investors. Sell 1 MDT: Despite its stable market presence, MDT's higher valuation and lower dividend yield compared to BMY, coupled with less impressive profitability indicators, suggest that it may not offer the same level of value or income potential in the current market environment.
N
by joyny
MDT Medtronic plc Options Ahead of EarningsIf you haven`t bought the previous dip in MDT: Then analyzing the options chain and the chart patterns of MDT Medtronic plc prior to the earnings report this week, I would consider purchasing the 75usd strike price at the money Calls with an expiration date of 2023-11-24, for a premium of approximately $1.24. If these options prove to be profitable prior to the earnings release, I would sell at least half of them. Looking forward to read your opinion about it.
NLong
by TopgOptions
Argus Market Mover on 06/20/2023: MDTcopy & paste directly from Argus, Medtronic is one of the world's largest medical technology and solutions companies. The company’s devices focus on cardiac rhythm management, spinal and surgical navigation technologies, treatments for diabetes and neurological conditions, vascular therapies, and cardiac surgery. MDT has been a poor performer versus the S&P 500 and Healthcare sector since April 2020, after nice outperformance versus the SPX from mid-2012 to mid-2016. The stock had a nice run from 6/2012 until its latest peak in 8/2021. The shares then were smacked to $75 in 11/2022 from $129. MDT traced out a double bottom and broke out on April 24 with huge volume after FDA approval of the company’s diabetes device. After that, the stock moved to $91 and close to its August 2022 high. The shares then were hit again, falling back to $81. We have seen a nice bullish reversal after MDT bounced off its 200-day. Chart and moving-average support are at $82 and we would put a stoploss just below there. We would take profits at $100, with larger longterm gains possible.
NLong
by KhanhC.Hoang
Campaign Trading Medtronic to the $130 zoneyep ... Medtronic has been taking advantage of A.I. for years. "By harnessing the power of AI, data analytics, and sensors, Medtronic's healthcare technologies are helping clinicians create individualized treatment plans to achieve better outcomes for more people in more places. From the world’s first hybrid closed-loop insulin delivery system to robotic-assisted surgery, these devices are ushering in a new era in patient care. "
NLong
by KhanhC.Hoang
MDT Entry, Volume, Target, StopWhen price clears 92.39 With daily volume greater than 6.875M Target: 109.00 area Depending on your risk tolerance: 86.68 gets you 3/1 Risk/Reward, however I recommend your stop be a bit tighter, maybe slightly under the low (89.43) on March 2nd. Caution: Earnings on May 25th, Resistance @ 95.60 This trade idea is not trade advice. This idea is strictly based on my ideas and technical analysis. Not due diligence or fundamental analysis was performed while evaluating this trade idea. Do not take this trade based on my idea, do not follow anyone blindly, do your own analysis and due diligence. I am not a professional trader.
NLong
by tradepatiently